Soligenix, Inc. (SNGX) announced a publication describing the preclinical efficacy of a single-vial, bivalent vaccine providing protection against both Sudan ebolavirus and Marburg marburgvirus infections. The company said the published paper describes the potency of the bivalent formulation against both viruses, showing 100% protection in the most rigorous non-human primate challenge models.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Shares of Soligenix are up 14% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.